Table 2.
Infections.
| Infection type | Case (n = 169) | Control (n = 297) | Total (n = 466) |
|---|---|---|---|
| Abscess | 7 (4.1%) | 1 (0.3%) | 8 (1.7%) |
| Bacteremia | 14 (8.3%) | 23 (7.7%) | 37 (7.9%) |
| BK nephropathy | 4 (2.4%) | 3 (1.0%) | 7 (1.5%) |
| BK viremia | 9 (5.3%) | 37 (12.5%) | 46 (9.9%) |
| Candida | 3 (1.8%) | 2 (0.7%) | 5 (1.1%) |
| Clostridioides difficile associated disease | 9 (5.3%) | 10 (3.4%) | 19 (4.1%) |
| CMV disease | 3 (1.8%) | 0 (0.0%) | 3 (0.6%) |
| CMV viremia | 24 (14.2%) | 40 (13.5%) | 64 (13.7%) |
| EBV viremia | 2 (1.2%) | 6 (2.0%) | 8 (1.7%) |
| Herpes simplex (disseminated) | 1 (0.6%) | 0 (0.0%) | 1 (0.2%) |
| JC polyoma virus | 0 (0.0%) | 1 (0.3%) | 1 (0.2%) |
| VZV (localized) | 2 (1.2%) | 0 (0.0%) | 2 (0.4%) |
| Mold infection | 1 (0.6%) | 0 (0.0%) | 1 (0.2%) |
| Mycobacteria | 0 (0.0%) | 1 (0.3%) | 1 (0.2%) |
| Nocardia | 1 (0.6%) | 4 (1.3%) | 5 (1.1%) |
| Other | 11 (6.5%) | 24 (8.1%) | 35 (7.5%) |
| Pneumocystis jirovecii pneumonia (PJP) | 0 (0.0%) | 1 (0.3%) | 1 (0.2%) |
| Pneumonia requiring admission | 6 (3.6%) | 13 (4.4%) | 19 (4.1%) |
| Pulmonary coccidioidomycosis | 2 (1.2%) | 1 (0.3%) | 3 (0.6%) |
| Pyelonephritis | 10 (5.9%) | 9 (3.0%) | 19 (4.1%) |
| Symptomatic UTI | 60 (35.5%) | 121 (40.8%) | 181 (38.9%) |
All infections identified in this study, with a breakdown between the case and control cohorts. Other infections: parvovirus (4), norovirus (4), coronavirus (not SARS-CoV-2) upper respiratory tract infection (4), rhinovirus (3), parainfluenza virus (2), salmonella gastroenteritis (2), bacillus cereus colitis (2), unspecified colitis (2), influenza virus URI (1), west nile virus meningitis (1), human papilloma virus (1), hepatitis B (1), unspecified osteomyelitis (1), necrotizing fasciitis (1), human metapneumovirus (1), RSV bronchitis (1), orchitis (1), cellulitis (1), legionella pneumonia (1), enteropathogenic E. coli gastroenteritis (1).